Preventive surgical procedures for inherited risk of breast cancer;Preventief chirurgisch ingrijpen bij erfelijke belasting voor borstkanker

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 48, 2005, Pages 2663-2667

  Menke Pluymers, M B E ^a   Seynaeve, C ^a   Van Geel, A N ^a   Klijn, J G M ^a   Meijers Heijboer, E J ^a   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; BREAST SURGERY; CANCER CENTER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; GENE MUTATION; GENETIC RISK; HETEROZYGOTE DETECTION; HIGH RISK POPULATION; HUMAN; MASTECTOMY; MEDICAL DECISION MAKING; ONCOGENE; OVARY CANCER; PHYSICAL EXAMINATION; REVIEW;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASTECTOMY; MUTATION; RISK FACTORS; RISK MANAGEMENT;

EID: 28444453990     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Visser O, Siesling S, Dijk JAAM van, editors. Incidence of cancer in the Netherlands 1999/2000. Utrecht: Vereniging van Integrale Rankercentra; 2003.
2. Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet. 1998;32:95-121.
3. Kwaliteitsinstituut voor de Gezondheidszorg CBO (CBO). Richtlijn 'Het mammacarcinoom: screening en diagnostiek'. Utrecht: CBO; 2000.
4. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-30.
5. Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer. 2000;83:384-6.
6. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328-35.
7. Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002;359:1471-7.
8. Seynaeve C, Verhoog LC, Bosch LM van de, Geel AN van, Menke-Pluymers M, Meijers-Heijboer EJ, et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer. 2004;40:1150-8.
9. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427-37.
10. Klijn JGM, Brekelmans CTM, Koning HJ de, Kriege M, Tibben A. Impact van regelmatige controle (screening) bij vrouwen met een verhoogd risico op borstkanker vanwege een familiaire predispositie. Eindrapport Ontwikkelingsgeneeskunde Project OG 98-03. Rotterdam: Erasmus MC; 2004.
11. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-15.
12. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300.
13. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356:1876-81.
14. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633-7.
15. Meijers-Heijboer H, Geel B van, Putten WL van, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159-64.
16. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, Veer L van 't, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055-62.
17. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 2000;355:2015-20.
18. Geel AN van, Contant CM, Wai RT, Schmitz PI, Eggermont AM, Menke-Pluijmers MM. Mastectomy by inverted drip incision and immediate reconstruction: data from 510 cases. Ann Surg Oncol. 2003;10:389-95.
19. Bresser P, Seynaeve C, Gool AR van, Brekelmans CT, Meijers-Heijboer EJ, Geel AN van, et al. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg. [ter perse].
20. Contant C, Menke-Pluymers M, Seynaeve C, Tjong Joe Wai R, Gool A van, Bresser P, et al. Cosmetic outcome of prophylactic mastectomy followed by immediate breast reconstruction using a subpectorally placed silicone prosthesis in women at risk of hereditary breast cancer or with a proven BRCA1 or BRCA2 germ-line mutation [abstract]. Eur J Cancer. 2004:abstract 380.
21. KWF-folder 'Erfelijke borst- en eierstokkanker'. Amsterdam: KWF Kankerbestrijding; 2003. p. 24-6.
22. Seynaeve C, Meijers-Heijboer H, Menke-Pluymers M, Putten W van, Bartels C, Crepin E, et al. Incidence of contralateral breast cancer and outcome after prophylactic mastectomy in BRCA mutation carriers with a history of unilateral breast cancer [abstract]. J Clin Oncol. 2002;20:426a.
23. Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2000;180:439-45.
24. McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19:3938-43.
25. Contant CME, Geel AN van, Holt B van der, Griep C, Tjong Joe Wai R, Wiggers T. Morbidity of immediate breast reconstruction (IBR) after mastectomy by a subpectorally placed silicone prosthesis: the adverse effect of radiotherapy. Eur J Surg Oncol. 2000;26:344-50.